ArticlePLoS computational biology2020
In silico mutagenesis of human ACE2 with S protein and translational efficiency explain SARS-CoV-2 infectivity in different species.
Article in PLoS computational biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Boswellic Acid Derived Molecules as SARS-Cov-2 Spike Protein Inhibitors: A Comprehensive Virtual Screening, Triplicate Molecular Dynamic Simulation and Biochemical Validation.Current medicinal chemistry · 2026Article
- PPAC: Predicting Protein-Protein Affinity Changes Induced by Amino Acid Mutations Using Protein Large Language Models.ACS omega · 2025Article
- Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature.BMC infectious diseases · 2024Article
- Plasma proteome dynamics of COVID-19 severity learnt by a graph convolutional network of multi-scale topology.Life science alliance · 2023Article
- Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein.Computational and structural biotechnology journal · 2023Article
- Structural heterogeneity and precision of implications drawn from cryo-electron microscopy structures: SARS-CoV-2 spike-protein mutations as a test case.European biophysics journal : EBJ · 2022Article
- Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2.One health (Amsterdam, Netherlands) · 2022Article
- Article
- Modeling mutational effects on biochemical phenotypes using convolutional neural networks: application to SARS-CoV-2.iScience · 2022Article
- A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues.bioRxiv : the preprint server for biology · 2022Article
- E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody.International immunopharmacology · 2022Article
- Investigating SARS-CoV-2 Susceptibility in Animal Species: A Scoping Review.Environmental health insights · 2022Article
- SARS-CoV-2 Virus-Host Interaction: Currently Available Structures and Implications of Variant Emergence on Infectivity and Immune Response.International journal of molecular sciences · 2021Review
- Exploring the therapeutic potential of marine-derived bioactive compounds against COVID-19.Environmental science and pollution research international · 2021Review
- Animal Transmission of SARS-CoV-2 and the Welfare of Animals during the COVID-19 Pandemic.Animals : an open access journal from MDPI · 2021Review
- Variation in predicted COVID-19 risk among lemurs and lorises.American journal of primatology · 2021Article
- Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets.Microorganisms · 2021Review
- Article
- Variation in predicted COVID-19 risk among lemurs and lorises.bioRxiv : the preprint server for biology · 2021Article
- Human Ace D/I Polymorphism Could Affect the Clinicobiological Course of COVID-19.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease COVID-19 constitutes the most severe pandemic of the last decades having caused more than 1 million deaths worldwide. The SARS-CoV-2 virus recognizes the angiotensin converting enzyme 2 (ACE2) on the surface of human cells through its spike protein. It has been reported that the coronavirus can mildly infect cats, and ferrets, and perhaps dogs while not pigs, mice, chicken and ducks. Differences in viral infectivity among different species or individuals could be due to amino acid differences at key positions of the host proteins that interact with the virus, the immune response, expression levels of host proteins and translation efficiency of the viral proteins among other factors. Here, first we have addressed the importance that sequence variants of different animal species, human individuals and virus isolates have on the interaction between the RBD domain of the SARS-CoV-2 spike S protein and human angiotensin converting enzyme 2 (ACE2). Second, we have looked at viral translation efficiency by using the tRNA adaptation index. We find that integration of both interaction energy with ACE2 and translational efficiency explains animal infectivity. Humans are the top species in which SARS-CoV-2 is both efficiently translated as well as optimally interacting with ACE2. We have found some viral mutations that increase affinity for hACE and some hACE2 variants affecting ACE2 stability and virus binding. These variants suggest that different sensitivities to coronavirus infection in humans could arise in some cases from allelic variability affecting ACE2 stability and virus binding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.